Lotus Pharmaceuticals and Teraju Pharma have entered a strategic partnership to market Lotus’s products in a range of therapeutic areas in Malaysia.
Teraju Pharma will be responsible for marketing and promoting the products using its relationships and infrastructure.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The company is a specialised pharmaceutical wholesaler and holds a licence, issued by the country’s ministry of health, to import non-registered pharmaceutical products, orphan drugs and other life-saving medicines.
It sources a wide range of branded or generic equivalent drugs from across the globe to meet the needs of the local market.
Lotus Pharmaceuticals CEO Petar Vazharov stated: “We are delighted at our new collaboration with Teraju.
“This partnership will enable us to establish a substantial presence in Malaysia, particularly in the oncology sector, which leverages high-quality manufacturing and a rich pipeline of products.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe company confirmed that the alliance is in line with its strategic plan to expand in Southeast Asia.
The collaboration will launch a portfolio of products in the therapeutic categories of ophthalmology, cardio-metabolic and oncology, commencing in the fourth quarter of 2023.
Lotus Pharmaceuticals, Alvogen and NRx Pharmaceuticals recently signed a global collaboration agreement for the development and commercialisation of NRX-101 to treat suicidal treatment-resistant bipolar depression (S-TRBD).
The company will buy worldwide rights for the therapy and handle its commercialisation activities in markets outside the US.
